660 per week means the sales reps are moving less than one script per day.
I think they are hiding how much volume they are moving.
In the month of march 1100 total scripts, so they roughly doubled the volume in one month.
Now to forecast script growth, do you want to go linear or exponential here?
If you chose linear then figure 1200 more scripts per month starting at 2500 that puts us at 10k+/- per month at the end of 2014. At $400/script that is only $12million per quarter.
If you go geometric and double each month starting now then you will have 5000 at the end of may
10,000 at the end of june, 20,000-july,40,000-august, 80,000-sept, 160,000-oct, 320,000-nov, 640,000 scrpts at the end of december.
So if you were a reporter, you could predict somewhere between those two numbers and still not be a total liar.
Given that the number of reps is not changing, you have to go more with the linear model.
The cartel must have a sham media company for press releases making sure that every outlet has a chance to distribute the lies.
I once started a company that saved the taxpayers lots of money and delivered superior service at the township level. The big players who stood to lose market share quickly spread their lies and threats. Every town board caved without question.
Good deeds do not go unpunished, and when corporate money is involved there is no shortage of elected representatives willing to never look at themselves in the mirror.
The trend for Sumavel has been up. Revenue from that alone has been 9million. Add to that the initial shipments of zohydro and some additional shipments to pharmacies that conservatively under ordered, and we have at least 20million in total revenue.
Earnings will depend on what expenses they amortize and what they deduct immediately.
The market should be interested primarily in the top line, but the bash articles will focus on expenses.
In the long run the companies who are fostering the anti-zohydro campaign because of their impending loss of market share, are shooting themselves in their remaining foot because in the effort to go after a competing product any laws made will have to abide the 14'th amendment and be applied to the whole class rather than just one individual.
The word they blacked out was that of the German WW2 single party, "Knot Zee". These hayoos have no discernment.
what he said. Especially the high road part.
They should be counter-suing for legal costs too.
Look at the wording of the Penn bill that just made it through committee, it's all Purdue. Why would each effort to smear and outlaw zohydro include wording about abuse deterrence formulations ?
Purdoody has probably dedicated 100million in this campaign, I hope we have a court somewhere that makes it cost them five times that.
Here is the story. It wa only a committee vote. Note, the author is republican and the lone dissenting voice was a democrat. Nobody has a monopoly on stupidity.
A pain pill that is up to 10 times stronger than hydrocodone could become harder to get in Pennsylvania.
The House Human Services committee passed a bill Tuesday that would require doctors to perform more steps before prescribing Zohydro, which the Food and Drug Administration recently approved. The bill would also require greater patient monitoring.
Zohydro will only make Pennsylvania's prescription drug addiction crisis worse, said Rep. Gene DiGirolamo, R-Bucks, the bill's sponsor. He was not aware of any precedent for singling out a single drug like this before, but said Zohydro warrants special treatment, not only because of its potency, but because the drug does not have a tamper-proof version, meaning it would be easier for addicts to crush and snort the pills.[this is obviously wording written by Purdue]
"It is absolutely going to cause people to die in Pennsylvania," DiGirolamo said.
How a prescription drug overdose kills a person
DiGirolamo originally wanted to ban Zohydro from being sold in the state, but a court overturned a similar law in Massachusetts. So this bill, as amended, includes the new restrictions.
The amendment would require doctors to:
-- Conduct and document a thorough medical evaluation.
-- Conduct and document a risk assessment.
-- Document in the medical record that the prescription of hydrocodone without an abuse-deterrent formulations required for the management of pain and that nothing else will effectively manage the severe pain.
-- Receive a signed informed consent form, including information from the drug insert.
-- Receive a chronic controlled substance treatment agreement that shall include conditions such as urine screening, pill counts, safe storage and disposal and other appropriate conditions as determined by the prescriber.
they spin what already exists to make it look like they are on the ball.
There are so many great deals in this market thanks to the shorts. All you have to do is watch for a company with good fundamentals and a one year low. Hold for a year and woohoo, royal double or triple in a year.
I especially take note of the high volume on an up day.
Decreasing debt, increasing day rates[generally over the last twelve months], backlog, Mexico coming on, adding to the strength of the liftboat market.
Good fundamentals at a two year low, Buffet and Graham would drool. Lynch too.
Government trying to destroy capitalism by limiting acetaminophen.
that's how some see it.
Just being a turd here. You know the game
Every day is a headfake. Take out the f and it's headache.
Hang tight boys and don't sell for a year because they are going to eff with this thing for a long time. Given the insane profits made by manipulators, probably forever. Maybe some day we will see a PE of .10 where we are earning 25.00 per share but pps is still at 2.50 and the shorters have shorted out three times the oustanding 140 million shares and Barrons is reporting that our earnings can't last and that the stock is going to zero, And Manchin is the head of the FDA. water running uphill, cats living with dogs....
Usually Globe picks up items and puts it on the wire. This company has been very quiet for six months. Either a big bad coming or a big good surprise.
Where did Omar go?
The remaining text:
Given increasing concerns over the lack of abuse deterrent characteristics, all Zohydro ER transactions adjudicated against PMSI and Progressive Medical’s formularies will require prior authorization unless otherwise specified at the client level. It is not anticipated that the launch of Zohydro ER will lead to an overall increase in the use of long-acting opioid pain relievers. Based on historical data, it is likely that Zohydro ER will take over a percentage of the market share of currently available long acting opioid products.
Our various pharmacy partners including Kroger, Target, Walgreens, Walmart, Albertsons, Rite Aid, and Safeway have indicated that Zohydro ER will not be auto-stocked at their various locations. Most pharmacies will base future inventory decisions on demand, but can obtain Zohydro ER within a reasonable time period (e.g. overnight to 1-2 days) if a prescription is received at a particular location that does not stock this product.
Here is some but not all of the article.
March 13, 2014 4:28 pm
Late last week, California-based Zogenix launched its recently approved Zohydro® ER into the U.S. market despite ongoing criticism that the long-acting version of hydrocodone does not possess any notable abuse-deterrent properties. Intended for use in the treatment of pain severe enough to require around-the-clock pain relief and for which alternative therapy options have failed, Zohydro ER is the first long-acting hydrocodone product to hit pharmacy shelves. Until the launch of Zohydro ER, hydrocodone was only available in the United States in combination products with non-opioid constituents (e.g. acetaminophen, ibuprofen, chlorpheniramine, etc.) and was classified as a Schedule III controlled substance; however, Zohydro ER is classified as a Schedule II controlled substance due to its single-entity composition. Many patient safety advocacy groups are concerned about the lack of abuse-deterrent properties of this drug, given the FDA’s recent unpredictable actions regarding the approval of long-acting opioid pain relievers. Zogenix indicates that an abuse-deterrent formulation is currently being developed and may be available within the next three years, pending FDA approval.
Price (AWP) per Unit Amount
At this point in time, there is no action necessary on behalf of workers’ compensation payors regarding the official launch of Zohydro ER. As your workers’ compensation pharmacy benefits partner, PMSI and Progressive Medical strive to provide you with up-to-the-minute information on medication changes that may affect your patient population. Given increasing concerns over the lack of abuse deterrent characteristics, all Zohydro ER transactions adjudicated against PMS